What is the 13F Pro Quality Score for NEO?

13F Pro ranks NEOGENOMICS INC (NEO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View NEO's current score at https://13fpro.ai/research/NEO (free sign-up required for the full ranking).

Which hedge funds own the most NEO stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of NEO include BlackRock,, TENOR CAPITAL MANAGEMENT Co., L.P., BRAIDWELL. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/NEO as soon as new 13F filings post.

Where does 13F Pro source NEO data?

All NEOGENOMICS INC fundamentals and ownership data come directly from SEC EDGAR. NEOGENOMICS INC files with the SEC under CIK 1077183. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is NEO in?

NEOGENOMICS INC (NEO) is classified in the Technology sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/technology.

How often is NEO research updated on 13F Pro?

NEO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

NEOGENOMICS INC(NEO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Technology →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1077183 NEO stock profile & AI dashboard →

13F Pro Quality Score

34.6/100

Rank #2,190 of 2,879 stocks

View Technology peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

66.5/100

Profitability

16.9/100

Balance Sheet

19.1/100

Earnings Quality

30.0/100

Free Cash Flow

25.4/100

Institutional Flow

42.2/100

Revenue Scale

43.1/100

Dilution Risk

24.0/100

NEO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for NEOGENOMICS INC (NEO), a Technology sector company. 13F Pro's AI-powered ranking engine scores NEO at 34.6/100 on a 32-signal composite quality model, placing it at rank #2,190 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include profitability (16.9) and balance sheet strength (19.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 24.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), NEOGENOMICS INC reports quarterly revenue of $186.7M, net income of $-17.1M, free cash flow of $-13.1M. Top institutional holders of NEO by reported 13-F value include BlackRock,, TENOR CAPITAL MANAGEMENT Co., L.P., BRAIDWELL, based on the most recent SEC filings. NEO trades on the Nasdaq exchange and files with the SEC under CIK 1077183. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NEO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NEOGENOMICS INC directly from SEC EDGAR. NEOGENOMICS INC's 13F Pro composite quality score has ranged between 8 and 60 since 2026, currently 34.6 — an improving long-term trajectory across 36 quarterly and live scoring snapshots.

✦

Fun facts about NEOGENOMICS INC

Quirks, history, and lore behind NEO — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare technology company · listed on Nasdaq · headquartered in Florida · operates a nationwide network of specialty laboratories.
2
The Numbers
Annual revenue in the range of $500–600 million, generated almost entirely from cancer diagnostics testing processed at labs across the country.
3
The History
Founded around the turn of the millennium, it grew rapidly through acquisitions to become one of the largest dedicated oncology-focused lab companies in the United States.
4
The Secret
Its clients are oncologists and pathologists, not patients — it's the behind-the-scenes lab doing the genetic and molecular testing that helps doctors decide how to treat cancer.
5
The Lore
The company expanded into pharma services, partnering with drug makers who need clinical trial testing — turning cancer diagnostics into a two-sided business.
6
The Giveaway
Its name literally means new genomics, and its ticker — NEO — fits a company that believes the future of cancer care lives in your DNA.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$186.7M

Net Income

Q1 2026

$-17.1M

Free Cash Flow

Q1 2026

$-13.1M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+10.1% YoY

$727.3MFY 2025

FY22 $509.7MFY23 $591.6MFY24 $660.6MFY25 $727.3M

Net Income

-37.2% YoY

$-108.0MFY 2025

FY22 $-144.0MFY23 $-88.0MFY24 $-78.7MFY25 $-108.0M

Operating Income

-25.8% YoY

$-115.9MFY 2025

FY22 $-157.6MFY23 $-107.7MFY24 $-92.1MFY25 $-115.9M

Total Assets

-17.0% YoY

$1.36BFY 2025

FY22 $1.74BFY23 $1.68BFY24 $1.64BFY25 $1.36B

Total Debt

-53.9% YoY

$341.9MFY 2025

FY22 $535.4MFY23 $538.2MFY24 $741.9MFY25 $341.9M

Op. Cash Flow

-25.5% YoY

$5.2MFY 2025

FY22 $-66.0MFY23 $-2.0MFY24 $7.0MFY25 $5.2M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019
Revenue	$727.3M +10.1%	$660.6M +11.6%	$591.6M +16.1%	$509.7M +5.2%	$484.3M +18.5%	$408.8M
Net Income	$-108.0M -37.2%	$-78.7M +10.5%	$-88.0M +38.9%	$-144.0M -1700.0%	$-8.0M -199.9%	$8.0M
Operating Income	$-115.9M -25.8%	$-92.1M +14.5%	$-107.7M +31.6%	$-157.6M -32.7%	$-118.8M -1013.1%	$13.0M
Total Assets	$1.36B -17.0%	$1.64B -2.6%	$1.68B -3.4%	$1.74B -6.9%	$1.87B +163.5%	$709.5M
Total Debt	$341.9M -53.9%	$741.9M +37.8%	$538.2M +0.5%	$535.4M +0.3%	$533.7M +383.2%	$110.5M
Operating Cash Flow	$5.2M -25.5%	$7.0M +459.6%	$-2.0M +97.0%	$-66.0M -147.0%	$-26.7M -214.4%	$23.4M

AI Insight: NEO Financial Trends

NeoGenomics shows revenue growth from $165M to $187M but operating losses persist with significant debt reduction from $742M to $342M.

• Revenue grew 13% from $165M in Q2 2024 to $187M in Q1 2026.

• Total debt reduced significantly from $742M in Q4 2024 to $342M in Q4 2025.

• Operating losses narrowed from $-28M in Q1 2025 to $-18M in Q1 2026.

⚠ Company remains unprofitable with operating losses in every quarter despite revenue growth.

⚠ Operating cash flow turned negative $-8M in Q1 2026 after positive $1M in Q4 2025.

⚠ Equity declined from $916M in Q2 2024 to $829M in Q1 2026.

AI Insight: NEO Ratio Trends

NeoGenomics showed significant margin improvement in Q4 2025 with operating losses narrowing to -7.0% from -26.3% in Q2 2025, though Q1 2026 saw some deterioration.

• Operating margin improved dramatically from -26.3% in Q2 2025 to -7.0% in Q4 2025, the best performance since Q4 2024.

• ROIC recovered from -22.3% in Q2 2025 to -4.5% in Q4 2025, matching the prior year level.

• Debt-to-equity ratio decreased from 0.82 in Q4 2024 to 0.41 in Q4 2025, indicating deleveraging.

⚠ Operating margin deteriorated from -7.0% in Q4 2025 to -9.8% in Q1 2026, breaking the improvement trend.

⚠ Company remains unprofitable across all metrics with negative returns on equity, assets, and invested capital.

Get alerted when NEO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for NEOGENOMICS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of NEO

BlackRock, Inc.
$148.1M19,957,502 sh
TENOR CAPITAL MANAGEMENT Co., L.P.
$99.5M108,050,000 sh
BRAIDWELL LP
$91.8M100,381,000 sh
First Light Asset Management, LLC
$72.2M9,729,978 sh
Greenhouse Funds LLLP
$67.5M9,100,103 sh
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$66.7M72,689,000 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$56.6M7,622,187 sh
FIRST TRUST ADVISORS LP
$45.7M6,162,371 sh
VANGUARD CAPITAL MANAGEMENT LLC
$42.0M5,655,823 sh
BRAIDWELL LP
$41.7M5,617,402 sh

Fund	Value	Shares
BlackRock, Inc.	$148.1M	19,957,502
TENOR CAPITAL MANAGEMENT Co., L.P.	$99.5M	108,050,000
BRAIDWELL LP	$91.8M	100,381,000
First Light Asset Management, LLC	$72.2M	9,729,978
Greenhouse Funds LLLP	$67.5M	9,100,103
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	$66.7M	72,689,000
VANGUARD PORTFOLIO MANAGEMENT LLC	$56.6M	7,622,187
FIRST TRUST ADVISORS LP	$45.7M	6,162,371
VANGUARD CAPITAL MANAGEMENT LLC	$42.0M	5,655,823
BRAIDWELL LP	$41.7M	5,617,402

More Technology Companies

View all Technology →

AGILENT TECHNOLOGIES, INC.

AAOI

APPLIED OPTOELECTRONICS, INC.

AAPL

Apple Inc.

ABNB

Airbnb, Inc.

ACCL

Acco Group Holdings Ltd

ACCS

ACCESS Newswire Inc.

ACFN

ACORN ENERGY, INC.

ACIW

ACI WORLDWIDE, INC.

Put NEO on your watchlist

Track score changes the day NEOGENOMICS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is NEO a good stock to buy?

13F Pro's AI-powered analysis of NEOGENOMICS INC (NEO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Technology sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NEO are available on the NEO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own NEO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NEO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of NEOGENOMICS INC's investment landscape.